The US FDA said it is considering a faster Phase I “clinical trial notification” pathway for certain first-in-human studies, aiming to reduce time and duplication in the earliest stages of development. The proposal is included in the agency’s $7.2 billion budget request for 2027. Under existing rules, sponsors must complete FDA review and a separate institutional review board process before they can begin advertising and recruiting for first-in-human studies. The new approach would provide an alternative route for trials where sponsors can already support the regulatory standard with validated non-animal methods. For smaller biotechs facing higher barriers in global early-stage hubs like China and Australia, the FDA’s described pathway could shift competitive timing—if implemented with sufficient clarity on acceptable data packages.